Brain zaps aim to revive emotion and drive in schizophrenia
NCT ID NCT07559084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new type of transcranial magnetic stimulation (TMS) that targets three brain areas at once to help with negative symptoms of schizophrenia, like lack of motivation, emotion, or social interest. Researchers will enroll 64 people with first-episode schizophrenia to see if this multi-target approach is safe and reduces these symptoms better than standard care. Participants will receive the TMS treatment while continuing their usual medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
repetitive transcranial magnetic stimulation (rTMS) device
What this could lead to
If it works, this could offer a new, non-drug way to reduce negative symptoms of schizophrenia, such as social withdrawal and low motivation.
What could go wrong
This is an early, small trial (64 people) testing a new targeting approach. It may not show clear benefit, and results may not apply to everyone with schizophrenia.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Mental Health Center
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••